David B. Klein

David is the former Managing Director at Opus Point Partners which created, financed, & operated 10+ science companies including Cougar Biotechnology (CGRB), Chelsea Therapeutics (CHTP), TG Therapeutics (TGTX), Assembly Biosciences (ASMB), Tracon Pharmaceuticals (TCON), Fortress Biotech (FBIO), and Ziopharm Oncology (ZIOP).